Medicine (Baltimore). 2025 Jul 18;104(29):e43414. doi: 10.1097/MD.0000000000043414.
ABSTRACT
BACKGROUND: This study evaluates the efficacy and side effects of different doses of erythromycin in patients with stable non-cystic fibrosis bronchiectasis (NCFB).
METHODS: Altogether, 148 patients diagnosed with stable NCFB were enrolled in this study and randomly assigned to one of the following 4 treatment groups: Group A received erythromycin 250 mg/d; Group B received erythromycin 375 mg/d; Group C received erythromycin 500 mg/d; and Group D received a placebo. Each group consisted of 35 patients. The dataset comprised lung function data and computed tomography, St. George respiratory questionnaire, modified Medical Research Council, bronchiectasis severity index (BSI), and exacerbations, FEV1, age, chronic colonization, extension, dyspnea scores, which were collected before and at 6 months after treatment. These were subjected to a univariate analysis.
RESULTS: Groups C and D exhibited significant differences in forced expiratory volume in 1 second, forced vital capacity, quality of life, and computed tomography Bhalla, BSI, and E-FACED scores (P < .05). Additionally, Groups B and D demonstrated significant differences in forced vital capacity and St. George respiratory questionnaire, BSI, and E-FACED scores (P < .05). Contrarily, Group A exhibited nonsignificant differences.
CONCLUSION: The oral erythromycin regimen at a dose of 500 mg/d can improve the lung function and quality of life of stable NCFB patients.
PMID:40696686 | DOI:10.1097/MD.0000000000043414
